| 潘汉博,林妙满,龚一富,等.海洋天然产物对抗阿尔茨海默症的研究进展[J].中国海洋药物,2019,38(2):73-82. |
| 海洋天然产物对抗阿尔茨海默症的研究进展 |
| Research progress of the marine-derived compounds with anti-Alzheimer’s potential |
| 投稿时间：2019-03-02 修订日期：2019-03-17 |
| DOI： |
| 中文关键词: 阿尔茨海默症 海洋天然产物 β淀粉样蛋白 乙酰胆碱酯酶 神经保护 |
| English Keywords:Alzheimer |
| Fund Project: |
|
| 摘要点击次数: 6001 |
| 全文下载次数: 738 |
| 中文摘要: |
| 阿尔茨海默症（AD）是老年人群发病率最高的神经退行性疾病，在老龄人口日益增多的现代社会引发严重经济和社会问题。但目前尚无治疗AD特效药物，现有药物仅能减轻AD症状，无法对因治疗。海洋生物数量庞大，能产生大量结构独特的天然产物，部分化合物具有神经保护作用，可能用于AD治疗。尤其是藻类来源的甘露寡糖二酸GV971已完成抗AD临床III期实验，是近十年最接近成功的抗AD药物，这一海洋来源的“中国新药”可能为全球AD患者提供新的希望。本文分类综述了从不同海洋生物，包括动物、植物及其他生物中提取的具有抗AD潜力的海洋天然产物的作用机理，以期为抗AD海洋天然药物开发提供参考。 |
| English Summary: |
| Alzheimer’s disease (AD), one of the most common neurodegenerative diseases among elderly, causes severe economic and social problems in modern society. However, there is no effective drug towards AD. Although existed anti-AD drugs can delay the progress of AD, and mitigate the disease symptom, they are not able to produce the disease-modifying effects. There are a huge number of marine organism which could produce natural products with a variety of pharmacology activities. Some of marine-derived compounds could exert neuroprotective effects, and might be used to treat AD. GV971, a mannooligosaccharide derived from brown algae, has finished phase III clinical trial in China, and might be the only anti-AD drug that closest to the success during the past 10 years. Therefore, this study summarizes the neuroprotective mechanisms of representative marine-derived anti-AD compounds, especially those isolated from marine animals, plants and other organisms, with the aim of providing further support for developing marine-derived anti-AD drugs. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|